SYS-CON MEDIA Authors: Liz McMillan, Carmen Gonzalez, Zakia Bouachraoui, Roger Strukhoff, David Linthicum

News Feed Item

Data Published in JACC: Cardiovascular Interventions Show that OrbusNeich's COMBO Dual Therapy Stent™ Reaches Primary Study Endpoint and Is Effective in Controlling Neointimal Proliferation

Results from REMEDEE Confirm that the COMBO Stent Is Non-Inferior to DES

HONG KONG, April 16, 2013 /PRNewswire/ -- OrbusNeich today announced that data from the REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) study published online in JACC: Cardiovascular Interventions demonstrated that the COMBO Dual Therapy Stent met the study's primary endpoint and was found to be effective in controlling neointimal proliferation. Specifically, the COMBO Stent was shown to be non-inferior to a drug eluting stent (DES) with respect to angiographic in-stent late lumen loss at nine months. Further, the COMBO Stent was shown to be safe, with an overall low rate of clinical events, a low rate of binary restenosis and no stent thrombosis (ST) observed up to 12 months.

The COMBO Dual Therapy Stent combines an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days with a proven pro-healing antibody surface coating.

At nine-month angiographic follow-up, the in-stent late lumen loss for the COMBO Stent was 0.39 +/- 0.45 mm compared to 0.44 +/- 0.56 mm for the control DES – the TAXUS® Liberte® paclitaxel-eluting stent. This is well below the threshold of 0.50 mm shown in the literature to be effective in preventing repeat revascularization.

At 12 months, the major adverse cardiac event (MACE) rate, defined as a composite of death, myocardial infarction (MI), emergent coronary artery bypass grafting (CABG), or target lesion revascularization (TLR) by repeat percutaneous transluminal coronary angioplasty (PTCA) or CABG, was 8.9 percent for the COMBO Stent group and 10.2 percent for the DES group. The clinically driven TLR rate and the clinically driven target vessel revascularization (TVR) were 4.9 percent and 6.5 percent, respectively, for the COMBO Stent group and 8.5 percent and 10.2 percent, respectively, for the DES group. No difference in mortality or occurrence of MI was observed, and no ST was reported in either group.

"Late and very late ST and a lack of durability of clinical effectiveness in the longer term remain issues with today's monotherapy DES," said Prof. Dr. Michael Haude of the Medical Clinic I, Lukaskrankenhaus, Neuss, Germany, and first author of the publication. "With the COMBO Dual Therapy Stent, we have an innovative stent technology that may accelerate early healing and neointimal stent strut coverage to allow for a shorter duration of dual antiplatelet therapy (DAPT) without compromising efficacy in respect to in-stent late lumen loss, restenosis and the need for reintervention. Additionally, intravascular ultrasound (IVUS)-virtual histology (VH) results revealed a bare metal stent (BMS)-like composition and morphology of the neointimal tissue for the COMBO Stent group versus DES, suggesting that the COMBO Stent may have the long-term safety profile of a BMS."

At nine months, IVUS revealed a numerically lower neointimal hyperplasia volume of 21.5 +/- 21.7 mm3 versus 25.9 +/- 18.7 mm3 for the COMBO Stent compared to DES. The in-stent volume obstruction was 15.24 +/- 14.22 percent for the COMBO Stent versus 14.59 +/- 8.38 for DES. An IVUS-VH comparison of the COMBO Stent with DES found a significantly less necrotic core area at maximum site on neointimal hyperplasia of 0.25 mm2 for the COMBO Stent versus 0.46 mm2 for DES and a less confluent necrotic core of 10 percent for the COMBO Stent versus 80 percent for DES.

In the study, 183 patients with de novo native coronary artery stenoses were randomized 2:1 to COMBO Stent or DES implantation. The study's primary endpoint was in-stent late lumen loss at nine months. Secondary endpoints included device, lesion and procedural success, all-cause and cardiac mortality, MI, MACE and ST, as well as clinically (ischemia) driven TLR and clinically (ischemia) driven TVR at 30 days, nine months and one through five years. In-stent and in-segment angiographic binary restenosis, in-stent and in-segment minimum lumen diameter and neointimal hyperplasia volume and percent in-stent volume obstruction were measured by IVUS at nine months. Baseline IVUS was performed in a subgroup of 66 patients (45 patients from the COMBO Stent group and 21 patients from the DES group), and IVUS follow-up at nine months consisted of 35 from the COMBO Stent group and 17 from the DES group.

The average pre-procedure reference vessel diameter (RVD) was 2.77 mm for the COMBO Stent group and 2.85 mm for the DES group, and the average lesion length was 13.69 mm for the COMBO Stent and 14.64 mm for DES. Of the lesions treated, 66.2 percent were type B2/C lesions in the COMBO Stent group and 61.0 percent were type B2/C in the DES group. For patients treated with the COMBO Stent, 33.1 percent had diabetes mellitus, compared to 37.3 percent for DES.

"The promising results from the first-in-man REMEDEE study not only confirm the COMBO Stent's safety and efficacy at one year, but they also differentiate the COMBO Stent from current monotherapy DES," said Stephen M. Rowland, Ph.D., vice president of research & development at OrbusNeich. "The COMBO Dual Therapy Stent reflects OrbusNeich's commitment to addressing the limitations of today's stent technology through ongoing innovation."

About the COMBO Dual Therapy Stent

The COMBO Dual Therapy Stent is the first dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the proven pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days.

OrbusNeich's patented endothelial progenitor cell (EPC) capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the COMBO Dual Therapy Stent, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit

Follow OrbusNeich on Twitter at, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel:

SOURCE OrbusNeich

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The platform combines the strengths of Singtel's extensive, intelligent network capabilities with Microsoft's cloud expertise to create a unique solution that sets new standards for IoT applications," said Mr Diomedes Kastanis, Head of IoT at Singtel. "Our solution provides speed, transparency and flexibility, paving the way for a more pervasive use of IoT to accelerate enterprises' digitalisation efforts. AI-powered intelligent connectivity over Microsoft Azure will be the fastest connected pat...
There are many examples of disruption in consumer space – Uber disrupting the cab industry, Airbnb disrupting the hospitality industry and so on; but have you wondered who is disrupting support and operations? AISERA helps make businesses and customers successful by offering consumer-like user experience for support and operations. We have built the world’s first AI-driven IT / HR / Cloud / Customer Support and Operations solution.
ScaleMP is presenting at CloudEXPO 2019, held June 24-26 in Santa Clara, and we’d love to see you there. At the conference, we’ll demonstrate how ScaleMP is solving one of the most vexing challenges for cloud — memory cost and limit of scale — and how our innovative vSMP MemoryONE solution provides affordable larger server memory for the private and public cloud. Please visit us at Booth No. 519 to connect with our experts and learn more about vSMP MemoryONE and how it is already serving some of...
Darktrace is the world's leading AI company for cyber security. Created by mathematicians from the University of Cambridge, Darktrace's Enterprise Immune System is the first non-consumer application of machine learning to work at scale, across all network types, from physical, virtualized, and cloud, through to IoT and industrial control systems. Installed as a self-configuring cyber defense platform, Darktrace continuously learns what is ‘normal' for all devices and users, updating its understa...
Codete accelerates their clients growth through technological expertise and experience. Codite team works with organizations to meet the challenges that digitalization presents. Their clients include digital start-ups as well as established enterprises in the IT industry. To stay competitive in a highly innovative IT industry, strong R&D departments and bold spin-off initiatives is a must. Codete Data Science and Software Architects teams help corporate clients to stay up to date with the mod...
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...
Platform9, the leader in SaaS-managed hybrid cloud, has announced it will present five sessions at four upcoming industry conferences in June: BCS in London, DevOpsCon in Berlin, HPE Discover and Cloud Computing Expo 2019.
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
When you're operating multiple services in production, building out forensics tools such as monitoring and observability becomes essential. Unfortunately, it is a real challenge balancing priorities between building new features and tools to help pinpoint root causes. Linkerd provides many of the tools you need to tame the chaos of operating microservices in a cloud native world. Because Linkerd is a transparent proxy that runs alongside your application, there are no code changes required. I...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
"NetApp's vision is how we help organizations manage data - delivering the right data in the right place, in the right time, to the people who need it, and doing it agnostic to what the platform is," explained Josh Atwell, Developer Advocate for NetApp, in this interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Druva is the global leader in Cloud Data Protection and Management, delivering the industry's first data management-as-a-service solution that aggregates data from endpoints, servers and cloud applications and leverages the public cloud to offer a single pane of glass to enable data protection, governance and intelligence-dramatically increasing the availability and visibility of business critical information, while reducing the risk, cost and complexity of managing and protecting it. Druva's...
Kubernetes as a Container Platform is becoming a de facto for every enterprise. In my interactions with enterprises adopting container platform, I come across common questions: - How does application security work on this platform? What all do I need to secure? - How do I implement security in pipelines? - What about vulnerabilities discovered at a later point in time? - What are newer technologies like Istio Service Mesh bring to table?In this session, I will be addressing these commonly asked ...
BMC has unmatched experience in IT management, supporting 92 of the Forbes Global 100, and earning recognition as an ITSM Gartner Magic Quadrant Leader for five years running. Our solutions offer speed, agility, and efficiency to tackle business challenges in the areas of service management, automation, operations, and the mainframe.